Eur. J. Haematol. 2020 Jan 31
PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Gotoh N, Minato Y, Saitoh T, Takahashi N, Kasamatsu T, Souma K, Oda T, Hoshino T, Sakura T, Ishizaki T, Shimizu H, Takizawa M, Yokohama A, Tsukamoto N, Handa H, Murakami H
Myelodysplastic syndromes (MDS), caused by various genetic mutations in hematopoietic stem cells, are associated with highly variable outcomes. Poly ( ...
Read More
Source: PubMed
Haematologica 2020 Jan 30
Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating therapy with decitabine.
Li H, Wang Y, Pang X, Xie C, Deeg HJ, Wang H, Wan T, Wu J, Guan F, Li X
Read More
Source: PubMed
Genes Dev. 2020 Jan 30
Recurrent SRSF2 mutations in MDS affect both splicing and NMD.
Rahman MA, Lin KT, Bradley RK, Abdel-Wahab O, Krainer AR
Oncogenic mutations in the RNA splicing factors SRSF2, SF3B1, and U2AF1 are the most frequent class of mutations in myelodysplastic syndromes and are ...
Read More
Source: PubMed
Einstein (Sao Paulo)
Myelodysplastic syndrome: validation of flow cytometry multilineage score system.
Araújo HV, Correia RP, Bento LC, Vaz ADC, Sousa FA, Alexandre AM, Schimidell D, Pedro EC, Ioshida MR, Barroso RS, Bacal NS
To validate multilineage score system correlating results of flow cytometry, cytogenetics, cytomorphology and histology from samples of patients with ...
Read More
Source: PubMed
Eur. J. Haematol. 2020 Jan 28
Clonal selection in therapy related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
Calleja A, Yun S, Moreilhon C, Karsenti JM, Gastaud L, Mannone L, Komrokji R, Ali NA, Dadone-Montaudie B, Robert G, Auberger P, Raynaud S, Sallman DA, Cluzeau T
Therapy related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/AML) are defined as complications of previous cytotoxic therapy. Azacitidin ...
Read More
Source: PubMed
